^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

CUE-102

i
Other names: CUE-102, CUE 102, LR19129, CUE102, LR 19129, LR-19129
Associations
Company:
Cue Biopharma, LG Chem
Drug class:
IL-2 stimulant, Wilms tumor 1 inhibitor
Related drugs:
Associations
4ms
CUE-102-01: A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers (clinicaltrials.gov)
P1, N=52, Active, not recruiting, Cue Biopharma | Recruiting --> Active, not recruiting
Enrollment closed • Metastases
|
WT1 (WT1 Transcription Factor) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
CUE-102
2years
A phase 1, open-label, dose escalation and expansion study of CUE-102 monotherapy in HLA-A*0201 positive patients with WT1-positive recurrent/metastatic cancers (SITC 2022)
Patients with colorectal and cisplatin-sensitive ovarian cancer must have documented disease progression to 2 prior systemic treatment regimens (CUE-102 will be ≥ 3rd line therapy); patients with Gastric/GEJ, pancreatic and cisplatin-resistant ovarian cancer must have documented disease progression to 1 prior systemic treatment regimens (CUE-102 will be ≥ 2nd line therapy). Results Trial is currently open and enrolling as of June 14, 2022.
Clinical • P1 data
|
CD8 (cluster of differentiation 8) • WT1 (WT1 Transcription Factor) • IL2 (Interleukin 2)
|
HLA-A*02:01 • WT1 expression • WT1 positive
|
cisplatin • CUE-102
over2years
A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers (clinicaltrials.gov)
P1, N=52, Recruiting, Cue Biopharma | Not yet recruiting --> Recruiting
Enrollment open
|
WT1 (WT1 Transcription Factor) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
WT1 expression • WT1 positive
|
CUE-102
over2years
New P1 trial
|
WT1 (WT1 Transcription Factor) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
WT1 expression • WT1 positive
|
CUE-102